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Abstract: Numerous eﬃcient synthetic methodologies have been elaborated for the synthesis of β -blockers since the
introduction of propranolol (a beta-blocker) in 1968. In this review, focus is placed on the more concise asymmetric and
bioenzymatic synthetic approaches attempted towards the synthesis of beta-blockers (betaxolol, metoprolol, sotalol, and
timolol).
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1. Introduction
Beta-blockers 1,2 have gained a remarkable place worldwide to treat several cardiovascular disorders such as
hypertension, angina pectoris, cardiac arrhythmia, and open angle glaucoma. 3,4 Beta-blockers also demonstrate
eﬃcacy to control adolescent and childhood disorders such as migraine headaches, dysrhythmias, anxiety, and
behavioral disorders. 5
Increased systolic and diastolic blood pressure can cause hypertension, which then can damage the renal,
cardiac, and brain blood vessels. 6 Beta-blockers block the action of the sympathetic nervous system of the
heart, thus reducing stress on the heart. Beta-blockers block beta-adrenergic substances such as epinephrine
(adrenaline) in the autonomic nervous system. They control the increase in blood pressure and thus inhibit the
damage to blood vessels. 3,4,7 Beta-blockers are incorporated in a wide range of clinical applications because
they block the adverse eﬀects of catecholamines on β -adrenergic receptors. 8
Most of the racemic beta-blocker drugs are eﬀective because their (S) -enantiomer shows great structural
similarities to the adrenergic hormone noradrenaline, whereas the (R) -enantiomer is responsible mostly for
side eﬀects. 9,10 (S)-betaxolol (1) 8 (Figure 1) demonstrates beta-blocking activity as a strong antiglaucoma
agent. 11−13
Metoprolol (2) ( β1 -blockade of catecholamines) (Figure 1) is widely used in the treatment of angina and
hypertension. 14 Metoprolol shows great potential to treat sympathetic nervous system disorders. Modified and
derived drugs of metoprolol are emphasized 15,16 due to their rapid elimination and low oral bioavailability. 17
∗ Correspondence:
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Figure 1. Structures of betaxolol and metoprolol beta-blockers.

Sotalol (3) (Figure 2) is most eﬀective in reentrant verticular arrhythmia and belongs to class III of
antiarrythmic drugs. 18−21 These drugs also have applications in the treatment of asthma, bronchitis, and
congestive heart failure. 22 The l -enantiomer of sotalol demonstrates 20 times more beta-blocker activity as
compared to d− enantiomer. 23,24

Figure 2. Structures of sotalol and timolol beta-blockers.

Timolol (4) (Figure 2) (or amphiphilic prodrugs such as nadolol 25 ) has also been found to be eﬀective in
hypertension and angina pectoris. 26,27 When administrated to the eyes, timolol exhibits the capability to lower
intraocular pressure, which is the base of its use to treat glaucoma. 28
2. Review of the literature
2.1. Synthesis of betaxolol
Considering the significance of beta-blockers, Manoury et al. 29 explained the synthesis of betaxolol by selective
benzylation of phenolic alcohol of 4-hydroxyphenethanoic acid. Reduction of the ethanoic acid group was
followed by alkylation with (bromomethyl)cyclopropane. Deprotection with H 2 followed by treatment with
isopropylamine furnished the betaxolol.
In continuation of their previous work, Manoury et al. 30 prepared pharmacologically active betaxolol.
(S)-(-)-2-phenyl-3-isopropyl-5-(hydroxylmethyl)oxazolidinyl tosylate (6) was used for the alkylation of phenol
5. 31 The resulting product 7 after acid-catalyzed hydrolysis aﬀorded the ( S) enantiomer of 1. Compound 5
was also allowed to react with (2 R)-3-(tosyloxy)-1,2-propanediol acetonide 8 32 followed by hydrolysis. The
resulting diol 9 was tosylated and converted to epoxide 10. Treatment of epoxide 10 with isopropylamine
furnished the (R) enantiomer of 1 (Scheme 1).
In order to check the drug metabolism, protein binding ability, and pharmacokinetics, Allen and Tizot 33
incorporated tritium in betaxolol, which exhibited high specific activity. Synthesis was initiated from the bromination of 4-[2-(cyclopropylmethoxy)ethyl]phenol, an intermediate employed for the preparation of betaxolol. 29,30
The product 2,6-dibromo phenol (11) was alkylated using excess epichlorohydrin under basic conditions to afford epoxypropane (12). Treatment of epoxypropane 12 with excess of isopropylamine at 100
194
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Scheme 1. Synthesis of betaxolol enantiomers.

provided 2,6-dibromobetaxolol (13). Debromination of 13 yielded betaxolol, which was purified and identified
by instrumental techniques. Exercising the same procedure with deuterium and tritium in the presence of
catalyst yielded [ 2 H 2 ]-betaxolol and [ 3 H]-betaxolol, respectively. The specific radioactivity of [ 3 H]-betaxolol
was 49C1/mmol and 98% radiochemical purity determined by thin layer radio chromatography (Scheme 2).

Scheme 2. Synthesis of tritium-labelled betaxolol.
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The provoking attention to pure enantiomers of beta-blockers encouraged researchers to follow the cheap
biotransformations. In this context, Bono and Scilimati 34 illustrated a chemoenzymatic pathway for the preparation of both ( R) and ( S) enantiomers of betaxolol. Lipase catalyzed kinetic resolution of the intermediate
(-)-17 and racemic betaxolol was carried out. Corresponding phenol 5 was treated with epichlorohydrin to
achieve the requisite epoxide 10. Ring opening of epoxide 10 with i -PrNH 2 aﬀorded racemic betaxolol (Scheme
3). The purified betaxolol was N, O -bisacetylated and subjected to enzymatic hydrolysis. Proteases, subtilisin, α -chymotrypsin, lipases, and porcine pancreatic lipase were employed in this screening, monitored by GC.
HPLC utilizing a CHIRALCEL OD column provided enantiomeric excesses of 16 and unreacted 15 (Scheme
4). The racemic 17 obtained from the acid treatment of 10 was also subjected to transesterification reaction
with vinyl acetate (acyl donor). The optically active (–)-17 and (+)-18 were converted to (–)-betaxolol (82%
ee, 76% yield) and (+)-betaxolol (60% ee, 76% yield), respectively (Scheme 5). 35−38 The recrystallization of the
hydrochlorides of the products was also carried out using diethyl ether to aﬀord (–)-betaxolol and (+)-betaxolol
with 91% and 75% ee, respectively.

Scheme 3. Synthesis of racemic betaxolol.

Scheme 4. Enzymatic hydrolysis of N , O -bisacetylated betaxolol.

In view of the advancements in synthetic methodologies for beta-blockers, Ippolito and Vigmond 39−41
described a number of protection/deprotection syntheses of betaxolol. 4-Hydroxyphenethanol (19) was converted to phenoxide anion using a base followed by reaction with epichlorohydrin. The yielded product 1-[4-(2hydroxyethyl)phenoxy]2,3-epoxypropane was treated with primary amine to provide the betaxolol intermediate.
To obtain the product, protection and deprotection were the necessary steps.
Protection and deprotection increase the synthetic steps, which lowers the yield. Wang et al. 42 elaborated
the protection free synthesis of betaxolol via selective alkylation. Treatment of 19 with a base provided
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Scheme 5. Synthesis of betaxolol from 10.

an oxygen dianion 20. Formation of oxygen dianion 20 removed the need for phenolic hydroxyl protection.
Reaction of oxygen dianion 20 with cyclopropylmethyl chloride aﬀorded 4-[(2-cyclopropylmethoxy)-ethyl]phenol
(5).

Treatment of intermediate 5 with epichlorohydrin yielded an epoxide, 1-{4-[2-(cyclopropylmethoxy)-

ethyl]-phenoxy} -2,3-epoxypropane (10) (Scheme 6). In another method 43 compound 19 was treated with
epichlorohydrin followed by treatment with (chloromethyl)cyclopropane to aﬀord 10. Betaxolol hydrochloride
was obtained when compound 10 was reacted with isopropylamine followed by the addition of HCl (Scheme 6).

Scheme 6. Synthesis of betaxolol hydrochloride from 19.

Hydrolytic kinetic resolution (HKR), the simplest approach for enantioselective preparation of stereoisomers, has attracted considerable attention from researchers. Joshi et al.44 utilized the said approach to synthesize ( S)-betaxolol in enantiomerically pure form. Benzylation of 2-(4-hydroxy phenyl) ethanol (19) in the
presence of phase transfer catalyst at ambient temperature resulted in 90% yield of regioselective product O alkylated 2-(4-benzyloxyphenyl)ethanol (21). Condensation of 21 with allyl bromide resulted in 1-(2-allyloxyethyl)-4-benzyloxy benzene (22) (98% yield). Furukawa modification of the Simmon–Smith reaction was utilized
for the cyclopropanation of the olefinic part of compound 22 to aﬀord compound 23 (95% yield). Debenzylation
of compound 23 followed by allylation provided compound 24 via 5, which on further treatment with mCPBA
in DCM under ambient conditions aﬀorded epoxide 10. Due to the fluidity of epoxide 10, it was incorporated
in the HKR approach. Using Jacobsen catalyst (Figure 3) and water at room temperature, HKR was performed
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SADDIQUE et al./Turk J Chem

for racemic epoxide 10 for 16 h, monitored by HPLC. Upon completion, the selective separation of (S)-epoxide
10 (43% yield, 99% ee) and ( R)-diol 9 (47% yield, 92% ee) was carried out over silica gel. HPLC using chiral
column CHIRALCEL OD was used to determine enantiomeric excess (ee). The epoxide 10 was allowed to react with i−PrNH 2 at ambient temperature, which furnished crude (S)-betaxolol. Pure (S)-betaxolol in 99%
ee was obtained after silica gel column chromatography (Scheme 7). Alternatively, 45 O−alkylation of 5 with
(R)-(–)-epichlorohydrin using a base aﬀorded a mixture of 10 and 17, which upon treatment with i -PrNH 2
and HCl furnished 1.HCl (Scheme 7).

Figure 3. Structure of (R,R) salen Co(III) catalyst-A (Jacobsen catalyst).

Scheme 7. Preparation of ( S) -betaxolol (1).
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In another methodology, Joshi et al. 46 selectively allylated the alcoholic group of 5 to aﬀord 4-(2allyloxy-ethyl)phenol (25) followed by the reaction of (R)-(-)-epichlorohydrin with phenol 25. The aﬀorded
intermediates 26 and 27 were then subjected to ring opening reactions with i− PrNH 2 in the presence of
a base to furnish ( S) -(-)-1-{4-[2-(allyloxy)-ethyl]phenoxy} -3-isopropylamino propan-2-ol (28). The Simmon–
Smith reaction converted the amino alcohol 28 to the requisite betaxolol (1) (Scheme 8).

Scheme 8. Synthesis of ( S) -betaxolol from compound 5.

Datta et al. 47 synthesized betaxolol via Heck arylation of vinyl ethers (Scheme 9). Synthesis was started
from a cheaper reagent.

p -chloronitrobenzene (29a). Palladium-catalyzed transvinylation of cyclopropylmethanol and ethyl vinyl ether using 2,2 ’ -bipyridyl ligand resulted in the formation of cyclopropylmethylvinyl
ether (30c). Compound 32 (60% yield) in highly regioselective coupling was prepared using Heck arylation
in aqueous DMF (Method A). The hydrogenation of the olefinic bond and nitro group of 32 furnished compound 33 (79% yield). Aryl chloride 29a was also converted directly in one step to 33 in greater yield.
Treatment of 33 with sodium nitrite (diazotization) and water resulted in phenol 5 (50% yield). Reaction of
(R)-3-isopropylamine 1,2-epoxypropane and then refluxing in ethanol for 8 h provided active (S) -betaxolol.
Treatment with dry HCl (gas) in dry ether and crystallization aﬀorded (S) -1.HCl (Scheme 10).
The envisioned eﬃcacy of HKR encouraged Muthukrishnan et al. 48 to employ this approach for the
concise synthesis of (S)-betaxolol. Reaction of 2-(4-hydroxyphenyl)ethanol (19) with (±) epichlorohydrin in
anhydrous 2-butanone, K 2 CO 3 base, and a phase transfer catalyst for 15 h under refluxing temperature resulted
in the racemate epoxide 34 (86% yield). HPLC-monitored HKR was performed for racemic epoxide 34 for 30
h at ambient temperature using Jacobsen catalyst and water in isopropanol. (S) -epoxide 34 (42% yield, 99%
ee) and ( R)-diol 35 (47% yield, 92% ee) were obtained over silica gel column chromatography. ( S)-epoxide 10
(47% yield, 92% ee) was achieved when hydroxyl group of ( S) -epoxide 34 was selectively O− alkylated using
chloromethylcyclopropane in the presence of KOt-Bu. Treatment of (S)-epoxide 10 with excess N -isopropyl
amine and refluxing for 2–10 h provided (S) -betaxolol. Silica gel column chromatography was then performed
to purify the crude ( S)-betaxolol (1) (96% yield, 99% ee) (Scheme 11).
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Scheme 9. Heck arylation of vinyl ethers 30.

Scheme 10. Synthesis of betaxolol.HCl (1).

Scheme 11. Synthesis of betaxolol by Muthukrishnan et al .

Working for developing short synthetic protocols for the synthesis of drugs, Zhang et al. 49 developed
a new synthetic approach for the synthesis of (S) -betaxolol administrating the kinetic resolution via chiral
auxiliary HCS (Scheme 12). The starting compound 19 was treated with epichlorohydrin and K 2 CO 3 in dry
acetone to achieve the racemic epoxypropane 5. Mixing of racemic epoxypropane 5 with 25-28% NH 3 yielded
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racemic β -amino alcohols 36. Manipulation of 36 with C12-higher carbon sugar (HCS) in methanol and traces
of p− TsOH yielded 37 and (S)−36 .Refluxing of ( S) -36 with isopropyl bromide and K 2 CO 3 in dry acetone
provided (S)-38 (98% yield, >99% ee). After protection of the amino group of (S)-38 with benzaldehyde, it
was treated with bromomethyl cyclopropane to give a pale yellow oil, which was mixed with 10% HCl and then
extracted with EtOAc to aﬀord the 1.HCl. Treatment with 10% NaOH followed by recrystallization from ether
provided concerned (S)-1 (yield 95%, ee > 99%) (Scheme 13).

Scheme 12. Synthesis of C-12 higher carbon sugar.

Scheme 13. Synthesis of betaxolol from compound 36.

Due to the eﬃciency of the enzymatic kinetic resolution approach, Li et al. 50 developed a novel approach that was more economical and stereoselective, for the direct resolution of betaxolol enantiomers and
its analogues. De-acetylation by enzyme catalyst was employed for kinetic resolution to aﬀord (S) -betaxolol.
A biocatalyst, the strain Rhodotorula mucilaginosa obtained from soil, was used for kinetic resolution of substrates 39 and 15 (acetylated intermediates). The lipase in the strain was highly selective for (R)-enantiomers.
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(S)-betaxolol was obtained directly by chemical methods from the corresponding intermediates. This method
proved to be economical and highly stereoselective (Scheme 14).

Scheme 14. Chemoenzymatic synthesis of ( S)− betaxolol.

In connection with their previous work, Li et al. 51 synthesized ( S)− betaxolol by chemoenzymatic
approach. Betaxolol after N , O -bisacetylation was also subjected to hydrolysis by diﬀerent strains. Two
out of 52 strains catalyzed the hydrolysis significantly but exhibited low selectivity. Alternatively compound 39
was prepared from 19. The complete kinetic resolution of 39 was performed to get the desired intermediates.
Phodotorula mucilaginosa DQ832198 showed better ee and enantioselectivity factor. To get better yield and
high yield, ( S) -1, afterN , O -bisacetylation, was subjected twice to kinetic resolution for 12 h. Intermediates
were converted to (S )-1.HCl (98% yield, 95% ee). 52 Recrystallization using Et 2 O enhanced the ee to 99%
(Scheme 15).

Scheme 15. Cont.

Synthesis and characterization of hydrochloride of betaxolol were carried out by Xu and Fang. 53 Selective
Williamson etherification between epichlorohydrin and p -hydroxy phenylethyl alcohol using 18% K 2 CO 3 acetone alkalescent solution was carried out to synthesize (1-[4-(2-Hydroxyethyl)phenoxy]-2,3-epoxypropane], a
betaxolol hydrochloride intermediate.
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2.2. Synthesis of metoprolol
The metabolism of metoprolol takes place through oxidative pathways. Shetty and Nelson 54 explained the chemical behavior of metoprolol. The asymmetric synthesis was also carried out along with the determination of
absolute configuration of benzylic hydroxylated metoprolol metabolites 46. Phenolic α -methoxyacetophenone
(41) 55 was obtained from 2-bromo-4’-hydroxy acetophenone (40). 56 Compound 41 on reaction with NaOH
and (RS ) 2,2-dimethyl-4-[(tosyloxy) methyl]-1,3-dioxolane (42) followed by hydrolysis provided diol 43. Tosylation and epoxidation of 43 followed by epoxide ring opening using isopropylamine and NH 4 Cl in catalytic
amount presented d-methoxyacetophenone (44). Chiral complex of borane and (2 S)-(–)-2-amino-3-methyl-1,1diphenylbutan-1-ol (45), synthesized from PhMgBr and (2S)-valine methyl ester hydrochloride, successfully
reduced the ketone 44 at room temperature as compared to modified lithium aluminum hydride reagent-1,1’-bi2-naphthol. Chromatographic separation of diastereomerically enriched and optically active compound 46 was
carried out from (2 S)-(–)-2-amino-3-methyl-1,1-diphenylbutan-1-ol (45). Reduction of ketone 44 with NaBH 4
yielded an equimolar mixture of two diastereomers of 46. The diastereomeric compositions and configurations
were also determined (Scheme 16).

Scheme 16. Synthesis of betaxolol derivatives 46.

Exploring the importance of radioactive labelled drugs, Shetty et al. 57 synthesized the deuterium labelled enantiomers of metoprolol. Chiral synthons 2,2-dimethyl-1,3-dioxolane-4-methanols were employed.
[D 6 ]-isopropyl amine and 4-(2-methoxyethyl)-2,6-[D 2 ]-phenol synthesized by DCl/D 2 O exchange and (4S) 2,2-dimethyl-1,3-dioxolane-4-[D 2 ]-4-methanol prepared by reducing (4S)-methyl-2,2-dimethyl-1,3-dioxolane-4carboxylate with LiAlD 4 were the key sources of deuterium. High enantiomeric excesses were obtained for all
the synthesized enantiomers.
In order to study the distribution and receptor binding studies of metoprolol, Antoni et al. 58 carried out
the synthesis of metoprolol incorporating the
N -alkylation of [2-

11

11

C-labelled technique. β -adrenergic ligand was synthesized from

C] isopropyl iodide. Treatment of [2- 11 C] isopropyl iodide 59 with metoprolol furnished

the 11 C-labelled metoprolol (1-isopropylamino)-3-(4-(2-methoxy ethyl) phenoxy)-2-propanol (Scheme 17).
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Keding et al.

60

carried out a facile synthesis of metoprolol. Treatment of (R) -3-chloro-1,2-propanediol

(47) with i-PrNH 2 using a base followed by the reaction with phenylchloroformate aﬀorded (S)-5-hydroxymethyl3-isopropyloxazolidin-2-one (48). Compound 49 was obtained when 48 was reacted with tolylsulfonyl chloride.
Treatment of 49 with 50 in the presence of a base and i−PrOH aﬀorded 51. The requisite compound (S) -2
was achieved by the hydrolysis of 51 (Scheme 18).

Scheme 17. Synthesis of isopropyl - 11 C-labelled metoprolol.

Scheme 18. Synthesis of metoprolol from compound 47.

Gurjar et al. 61 presented an eﬃcient and novel synthetic approach for the preparation of racemic metoprolol. Phenol 52 was subjected to modified Friedel–Crafts acylation 62 using chloroacetylchloride to achieve
2-chloro-1-(4-hydroxyphenyl) ethanone (53) (50% yield). Treatment of 53 with a mixture of MeOH/NaOMe at
room temperature yielded 41 (90% yield). Hydrogenation of 41 employing 10% Pd-C, 45 psi for 4 h aﬀorded
50 (96% yield). Intermediate 50 was converted to 54 (85% yield) by reacting with allyl bromide and K 2 CO 3
in acetone. To get the diol 55 (80% yield) dihydroxylation reaction 63 of 54 was performed using OsO 4 -NMO
(N -methyl morpholine- N −Oxide) in the presence of 1:2 acetone/water mixture at room temperature. Selective
mono-tosylation of 55 aﬀorded compound 56, which on treatment with methanolic sodium methoxide yielded
epoxide 57. Conversion of 57 into ( ±) metoprolol was carried out as reported previously (Scheme 19). 64
A more concise synthetic way was elaborated by Keding et al. 65,66 for the synthesis of S -metoprolol via an
intermediate prepared by reacting 4-[2-methoxyethyl]phenol with (S)-5-hydroxymethyl-3-isopropyloxazolidin2-one sulfonic acid ester.
Sasai et al. 67 synthesized metoprolol in an asymmetric way employing La-Li-BINOL (LLB) complex as
catalyst. Two-step synthesis of aldehyde 58 was carried out using 4-(2-methoxyethyl)phenol (50). Treatment
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of 58 with nitromethane using (R)-LLB (2 mol%) furnished nitroaldol 59 (99% ee, 88% yield). ( R)-LLB was
synthesized from LaCl 3. 7H 2 O. 68 Nitroaldol 59 (94% ee, 90% yield) was also obtained when 58 was treated with
(R)-LLB (5 mol%), synthesized from La(O- i -Pr) 3 . 69 Use of Pr-Li-BINOL catalyst (3 mol%) aﬀorded 59 (91%
ee, 82% yield). 70 (S)-metoprolol (2) was thus obtained from 59 using the mentioned conditions (Scheme 20).

Scheme 19. Synthesis of compound 2.

Scheme 20. Synthesis of ( S) -metoprolol from compound 50.

Iseki et al. 71 explained the synthesis of fluoro-substituted derivatives of metoprolol and checked their
biological eﬀectiveness. The synthetic process was started from the reaction of Na with phenol 50 and
chlorodifluoroacetic acid in refluxing dioxane; 72 then subsequent esterification provided α , α -difluoro ester
(60). Ester 60 was reduced to α ,α -difluoro aldehyde (61) using diisobutylaluminum hydride in ether at –
78

◦

C. 73 When aldehyde 61 was reacted with nitromethane at –40

◦

C using samarium-lithium-(R) -BINOL

catalyst (8 mol%), ( S)-1,1-difluoro-1-[4-(2-methoxyethyl)phenyloxy]-3-nitropropan-2-ol (62) 74 was obtained.
Enantiomerically pure nitroaldol adduct 62 was achieved from the mother liquor (65%, > 99% ee) after
recrystallization from ether/hexane. PtO 2 -catalyzed hydrogenation using acetone and methanol 67 executed
the reductive alkylation of homochiral (S)-nitroaldol 62 to ( S) -63. Similarly, when nitroaldol reaction of 61
was carried out in the presence of samarium-lithium-(S)-BINOL catalyst, the adduct (R)-62 was achieved,
from which metoprolol analog ( R)-63 was obtained in enantiomerically pure form (Scheme 21).
In connection to their previous work, Gurjar et al. 75 improved the synthetic methodology for (S) metoprolol via ( ±) -aryl glycidyl ethers that were kinetically resolved. (R, R)-salen Co(III)OAc and water
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were used for the kinetic resolution of ( ±)aryl glycidyl ethers. This technique provided high enantiomeric
excess of aryl glycidyl ether and 1-arylglycerol derivatives. This eﬃcient approach was employed to aﬀord
(S)− metoprolol.

Scheme 21. Synthesis of metoprolol analogues 63.

The use of novel and rapid instruments in the synthetic approach is always encouraged. Svensson et al. 76
employed modern techniques, Raman spectroscopy, and chemometrics to monitor the metoprolol synthesis.
Epoxide 57 was heated with isopropylamine in the presence of isopropanol. The reaction mixture was heated
applying a temperature gradient to produce 2.
Enantioselectivity and the facile availability of materials is always a major requirement of the pharmaceutical industries. Jung et al. 52 described the asymmetric synthesis of metoprolol and related metabolites.
Treatment of phenolic compounds 50, 64, and 65 with methanolic sodium hydroxide followed by the addition
of (R) and (S)-epichlorohydrin provided the 2,3-epoxypropoxy (R) and (S) enantiomers 57, 66, and 67,
respectively, which were further converted to the target compounds 2, 68, and 69. Hydrolysis of 69 using
KOH and methanol (1:1) aﬀorded the compound 70. Compound 70 was isolated and characterized as potassium salt after neutralization. The enantiomers of 70 were also prepared by reacting 65 with epichlorohydrin
enantiomers using excess triethylamine instead of NaOH. Optical purities of all enantiomers were determined
by HPLC (Scheme 22).

Scheme 22. Synthesis of metoprolol and its metabolites.

The cardiovascular activity of metoprolol derivatives inspired Melgar-Fernandez et al. 77 for the synthesis
of metoprolol analogues. Four novel stereoisomeric metoprolol derivatives carrying two stereogenic centers were
synthesized. The two diastereotopic methyl groups in metoprolol were converted into an alkyl group and alkyl
hydroxyl group. The synthetic route was started from the preparation of 4-(2-methoxyethyl) phenol (50) using
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Smith and co-workers’ methodology. 78 Reaction of racemic epichlorohydrin and aqueous NaOH solution with
′

phenol derivative 50 provided 2-[4-(2 -methoxyethyl)-phenoxymethyl]-oxirane (57) (90% yield). Side product
72 (10% yield) was separated over silica gel in column chromatography. The required diastereomeric derivatives
(2 S ,2’ S)-73 and (2R ,2’S)-73 were achieved when racemic epoxide 57 was treated with excessive amount of
(S)-2-amino-1-butanol in aqueous solution. The like 79 and pure diastereomers were crystallized out from
the aqueous phase. When (S)-2-amino-1-butanol was distilled oﬀ from the mother liquor, the diastereomeric
products (2 S ,2’S) -73 and (2 R ,2’S)-73 were obtained. A similar route was adopted using (R)-2-amino-1butanol to aﬀord the (2R ,2’R)-73 and (2S ,2’ R)-73 (Scheme 23).

Scheme 23. Synthesis of analogues 73 of metoprolol.

The envisioned eﬃcacy of hydrolytic kinetic resolution method (KHR) encouraged Muthukrishnan et
al.

48

to utilize it for the concise synthesis of ( S)-metoprolol incorporating 2-(4-hydroxy-phenyl) ethanol (19)

as the starting reagent. Treatment of intermediate ( S)-epoxide 34 with methyl iodide followed by the addition
of i-propylamine aﬀorded the crude (S)-metoprolol hydroiodide salt 74. Moreover, 6% ammonia solution was
used to free the crude ( S) -metoprolol hydroiodide salt. Silica gel column chromatography was performed to
purify the crude (S)-metoprolol 2 (97% yield, 96% ee) (Scheme 24).

Scheme 24. Synthesis of metoprolol from ( S) -34.

Use of chiral auxiliary HCS for the kinetic resolution by Zhang et al. 49 was developed for the synthesis
of ( S)-metoprolol. The starting reagent 50 was converted to metoprolol as described earlier (Scheme 25). 49
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Scheme 25. Synthesis of ( S) -metoprolol from compound 50.

A novel synthetic method for metoprolol was elaborated by Gaung-Wei et al.; 80 benzyl protection, Darzen
condensation, and rearrangement reaction converted the 4-hydroxy benzaldehyde to 4-benzyloxyphenylacetaldehyde. Addition reaction between sodium bisulfite and 4-benzyloxyphenylacetaldehyde followed by KBH 4
reduction, methylation, deprotection, etherification, and amination aﬀorded metoprolol (2).
Zheng et al. 81 synthesized the conjugates of metoprolol and saccharides by selective enzymatic approach. The eﬀect of organic solvents on the preparation of conjugates was also evaluated. Initially N (vinyloxycarbonyl)metoprolol derivatives (75 a–c) were synthesized by reacting metoprolol 2 and divinyl dicarboxylates in the presence of porcine pancreas lipase (PPL) and anhydrous carbon tetrachloride at 50

◦

C

(Scheme 26). Pure products were obtained by silica gel column chromatography. Highly regioselective reactions
of these derivatives with diﬀerent saccharides were carried out in the presence of alkaline protease from Bacillus
subtilis and pyridine at 50 ◦ C to aﬀord metoprolol-saccharide conjugates (75b i–v). All products were purified
by silica gel column chromatography (Scheme 27).

Scheme 26. Enzymatic synthesis of N -(vinyloxycarbonyl) metoprolol.

Scheme 27. Synthesis of metoprolol-saccharide conjugates.

The use of the chiral building blocks inspired Sonawane et al. 82 to report a short synthetic strategy
for the asymmetric synthesis of ( S)-metoprolol manipulating chiral building block (2S ,2 ′ S ,2” S) -Tris-(2,3epoxypropyl)-isocyanurate (S-TGT). 83 Treatment of S-TGT with phenol 50 aﬀorded pure oxazolidine 76.
(S)- N -alkylated oxazolidine (77) was achieved by reacting 76 with isopropyl bromide in NaH. Base hydrolysis
of 77 aﬀorded the desired (S) -metoprolol in quantitative yield (Scheme 28).
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Cheng et al. 84 reported the enantioselective synthesis of metoprolol under Sharpless asymmetric dihydroxylation. The process was performed using polymer ligand QN-AQN-gmnnOPEG-OMe, which could easily
be recovered. The synthesis started from the base catalyzed nucleophilic attack of phenol 50 on the allyl bromide
in dry acetone. The obtained compound 54 (87% yield) was subjected to asymmetric dihydroxylation with the
help of K 2 OsO 2 (OH) 4 , QN-AQN-OPEG-OMe using co-oxidants K 3 Fe(CN) 6 and K 2 CO 3 in a t -BuOH/H 2 O
system. Extraction with DCM, diethyl ether incorporation, and filtration aﬀorded the QN-AQN-OPEG-OMe
(95%). The obtained diol (S)-55 (96% ee) was subjected to epoxidation using trimethylorthoacetate, PPTS,
and AcBr in the presence of K 2 CO 3 . The synthesized epoxide on treatment with isopropylamine was converted
to ( S)-metoprolol (2) (62% yield, 91% ee) (Scheme 29).

Scheme 28. Synthesis of ( S) -metoprolol using S-TGT.

Scheme 29. Synthetic route of ( S) -metoprolol 2.

2.3. Synthesis of sotalol
The concise synthesis of d-sotalol was presented by Smith et al. 85 employing homogeneous chiral hydrogenation 86−88 of (4-isopropylaminoacetyl)methanesulfonanilide hydrochloride (78) over chiral BINAP 89,90 catalyst.
Rh complexed with ( R)-BINAP or (S)-BINAP provided the required d− sotalol (3) in the presence of a base
and methanol (Scheme 30).
Brodfuehrer et al. 91 performed the chiral synthesis of d−sotalol and evaluated it as an antiarrhythmia
agent. CBS reduction (Corey–Bakshi–Shibata reduction) of the carbonyl group of commercially available 4(chloroacetyl) methanesulfonanilide (79) using ( S)-MeCBSOB (80) in 1 M BH 3 -THF and t -BuOMe provided
the chiral chloroalcohol 81 92 (87.2% yield, 95% optical activity). The reaction of chiral chloroalcohol 81 with
isopropylamine at 130 ◦ C in a steel bomb provided 82, instead of d−sotalol. To avoid this problem, the
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Scheme 30. Catalytic asymmetric hydrogenation of 78.

hydroxyl group of 81 was first protected using triethylsilyl chloride (TESCl). Reaction of 83 with i -PrNH 2 at
130 ◦ C for 16.5 h in a steel bomb provided TES-protected d− sotalol (84) (30.1% yield). For good yield (98%
ee) d-sotalol 3 was slurried in 2-propanol with 3.9 N HCl in MeOH. d−Sotalol (58.3% yield) as a free base was
achieved by desilylation of 84 (Scheme 31). To eliminate the synthesis of TES-protected d− sotalol (84) and the
use of a steel bomb, compound 81 was reacted with saturated NaI in acetone for 9 h (Finkelstein conditions) 93
and subsequently protection of the hydroxyl group using TESCl aﬀorded iodosilyl ether (86) (77.3%) having
7%–9% of its chloro analogue 83. Treatment of 86 with i-PrNH 2 resulted in the formation of TES-protected
d−sotalol (84) (49.2% yield) (Scheme 32).

Scheme 31. Synthesis of sotalol 3.

Scheme 32. Synthesis of compound 84.

Due to interest in enantiomerically enriched diols, Phukan et al. 94 reported a new methodology to prepare
d−sotalol assessing Sharpless asymmetric dihydroxylation. The synthetic route was started from the synthesis
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of nitrostyrene (87) as reported previously. 95−97 The asymmetric dihydroxylation of 87 in the presence of a
chiral ligand DHQ-PHAL gave rise to the chiral diol 88. Treatment of diol 88 with SOCl 2 in pyridine aﬀorded
the cyclic sulfite, which upon oxidation with NaIO 3 and a catalytic amount of RuCl 3 , furnished the cyclic
sulfate 89. Refluxing of 89 with i-PrNH 2 in THF was carried out. Upon the completion of the reaction, the
reaction mixture was treated with 20% H 2 SO 4 followed by 20% NaOH to achieve nifenalol (90) (61% yield,
enantiomeric purity 96%). Chiral β -hydroxy propylamine (90) was obtained in quantitative yield under S N 2
mechanism. Reduction of nifenalol (90) with H 2 /Pd-C in the presence of ethanol at 50 psi pressure provided
amino compound 91. Treatment of 91 with methanesulfonyl chloride furnished the desired d− sotalol (3) (40%
yield). A side product was also obtained due to mesylation of the hydroxyl group. Column chromatography
was applied to separate the d−sotalol (optical purity 94%) (Scheme 33).

Scheme 33. Synthesis of sotalol from compound 87.

For the first time enzymatic resolution eﬀort was adopted by Kamal et al. 98 for the synthesis of both
enantiomers of sotalol. Reaction of aniline 92 with methane sulfonyl chloride in DCM and subsequent treatment
with chloroacetyl chloride provided the ketone 79. One pot reduction of 79 and then enzymatic resolution
of racemic chlorohydrins was the main step in this protocol. Reduction was performed using NaBH 4 and
moist neutral aluminum oxide in diisopropyl ether. Resolution of chlorohydrins was carried out in situ by
transesterification using immobilized Pseudomonas cepacia lipase (PS-C) and isopropyl acetate (acyl donor).
The resolved alcohol (–)-81 (90% ee) and acetate (+)-93 (94% ee) were treated with i -PrNH 2 to achieve the
sotalol (–)-3 (90% ee) and (+)-3 (94% ee) (Scheme 34).
For the facile synthesis of sotalol, Kapoor et al. 99 prepared and resolved the chiral bromohydrin, a
precursor to (S)-sotalol. The best strategy for the biocatalytic synthesis of (R) - and ( S)-2-bromo-1-(4nitrophenyl)ethanol (96) in high enantiomeric purity, was making use of three diﬀerent techniques. Monobromination of 4-nitroacetophenone (94) aﬀorded 4-nitrophenacyl bromide (95). The bioreduction of 95 using
diﬀerent dehydrogenases (reductase) provided 2-bromo-1-(4-nitrophenyl) ethanol (96) (Scheme 35). This approach did not provide convincing results. In terms of enantiopurity, Pichia capsulate and S. cerevisiae provided
(S)-96 (70%) and ( R)-96 (67.8%), respectively. The lipase-esterease catalyzed hydrolysis approach was manipulated, initiated by the reduction of 95 using NaBH 4 /MeOH to achieve (±)-96. Racemic alkyl acyl esters
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Scheme 34. Synthesis of sotalol from compound 92.

97a–c were stereoselectively hydrolyzed by a number of lipases/estereases (Scheme 36). The enantiopurity was
not improved by this approach for the hydrolyzed products. Commercial enzyme CRL hydrolyzed the butyl
ester 97c (60% ee, 47% conversion), while the Arthrobecter sp. provided better selectivity (75% ee) for the
acetate. Eﬀectiveness of co-solvent to improve selectivity was also checked. Transesterification was also performed using diﬀerent estereases. PS-C-II as a catalyst with vinyl acetate (acyl donor) and solvent provided
the best results. In order to improve the transesterification reaction by PS-C-II in a short time, various solvents
were employed. Transesterification proved to be the most eﬀective for the resolution of 96 racemic mixture
under optimum conditions (PS-C-II, 200 g/L conc., toluene). Toluene improved the reaction rate, aﬀorded the
eﬃcient resolution and complete conversion in a short time (Scheme 37).

Scheme 35. Bioreduction of 95.

To overcome the deficiency of easily available reagents, Blay et al. 100 adopted the highly stereoselective
Henry reaction to aﬀord ( S) -(+)-sotalol using appropriate aldehyde. The main feature of this synthesis is
the Henry reaction, which produced the desired nitro alcohol in high ee using aminopyridine copper complex
(98). Reaction between p -aminobenzaldehyde and mesyl chloride in pyridine yielded N −(4-formyl phenyl)
methanesulfonamide 99. Reaction of CH 3 NO 2 and diisopropyl ethyl amine (DIPEA) with aldehyde 99 in the
presence of 10 mol% of Cu(OTf) 2 -98 complex in ethanol at –30 ◦ C aﬀorded nitro alcohol 100 (65% yield, 92%
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Scheme 36. Lipase/esterase catalyzed kinetic resolution of acyl derivatives 97a–c.

Scheme 37. Transesterification of ( ±) -96 using PS-C-II.

Scheme 38. Enantioselective synthesis of ( S) -(+)-sotalol.
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ee). Catalytic hydrogenation 101 of compound 100 using 10% Pd/C in MeOH/EtOH (1:2) provided the amino
alcohol 101 in good yield. Compound 101 was reacted with acetone-NaBH 4 for reductive alkylation 102 to
achieve ( S)-(+)-sotalol (92% ee), which on further reaction with 5% HCl was converted to (S)-(+)-sotalol.HCl
(Scheme 38).
Using ruthenium catalyst, Lu et al. 103 cited the preparation of chiral halohydrins in an enantioselective
way, a precursor to ( S)-sotalol. In this approach diﬀerent ligands and a variety of surfactants were employed
for their asymmetric transfer hydrogenation eﬃcacy. Monobromination of p−nitroacetophenone incorporating
bromine in acetic acid aﬀorded the bromoketone 95. Asymmetric transfer hydrogenation of bromoketone over
L5-[RuCl 2 (p -cymene)] 2 catalyst (Figure 4) in HCOONa/H 2 O system yielded chiral bromoalcohol (S)-(+)-96
(93% ee). Reduction with Pt/C transformed the nitro group of the intermediate into an amino group, which
on further reaction with mesyl chloride in pyridine aﬀorded sulfonamide. Sulfonamide was subjected to S N 1
substitution reaction with i -propylamine, providing the concerned (S) -sotalol (35% yield).

Figure 4. Structure of L5 (R,R,R)-Cs-DPEN) or [Ru( p -cymene) Cl 2 ] 2 catalyst.

Scheme 39. Enantioselective synthesis of ( S) -sotalol from 95.

Shanghai-AoBo 104 presented the short synthesis of sotalol hydrochloride. Aniline was treated with mesyl
chloride to achieve N -phenylmethanesulfonamide, which on reaction with chloroacetyl chloride furnished N -[4(2-chloroacetyl)phenyl]methanesulfonamide. Addition of isopropylamine to N -[4-(2-chloroacetyl)phenyl]methanesulfonamide followed by reduction and saltification aﬀorded sotalol hydrochloride (64% yield).
2.4. Synthesis of timolol
Utilizing optically active precursors, Weinstock et al. 31 carried out the synthesis of timolol. In the first step,
(S)-3-tert-butylamino-1,2-propandiol (102) (54% yield) was obtained by treating (R)-glyceraldehyde with
H 2 /Pd and tert-butylamine. Condensation of 102 with 3-chloro-4-(N -morpholino)-1,2,5-thiadiazole (103)
using potassium tert-butoxide furnished the timolol levorotatory, separated as maleate salt in low yield (Scheme
40). Due to low yield and nonavailability of glyceraldehyde this methodology is restricted to the laboratory.
The base-sensitive nature of 4 (S) resulted in its equilibration with 104 (Smiles rearrangement), which
lowers the yield. Base sensitivity also caused the loss of side chains from 4 and 104 providing 3-hydroxy4-( N -morpholino)-1,2,5-thiadiazole anion 105 (Scheme 41). The encountered shortcomings were eliminated by
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protecting the secondary alcohol functionality of (S) -102 by treating with benzaldehyde resulting in oxazolidine
(109) formation. Reaction of 109 with 3-chloro-4-(N -morpholino)-1,2,5-thiadiazole (103) using potassium
tert-butoxide and subsequent hydrolysis provided timolol (50% yield) (Scheme 42). Alternatively treatment
of optically active epoxide 106 with sodium salt of 3-hydroxy-4-(N -morpholino)-1,2,5-thiadiazole (105) also
introduced the side chain amino-propanediol providing compound 4 (36% yield) (Scheme 42). To compensate
the need of ( R)-glyceraldehyde, aminoglycol (102) was synthesized alternatively. Reaction of D-mannitol1,2,5,6-bisacetonide (107) 105 with lead tetraacetate produced 2 equivalents of (R) -glyceraldehyde acetonide
(108). Reductive alkylation using t− BuNH 2 of 108 followed by hydrolysis furnished 102 (70% yield) (Scheme
43).

Scheme 40. Synthesis of thiadiazole 4.

Scheme 41. Cont.

In order to enhance the ocular delivery of timolol, Bundgaard et al. 106 synthesized timolol prodrugs.
Esters of timolol were also evaluated for their hydrolysis kinetics and lipophilicity. After maintaining suitable
pH and extraction of timolol maleate, excess of 3 M HCl in methanol was added to get timolol hydrochloride.
Slurry of timolol hydrochloride was prepared in benzene and then treated with appropriate acid chloride.
Separation of timolol esters (110–113) was also carried out (Scheme 44).
In continuation of their previous work, Bundgaard et al. 107 reported the synthesis of diﬀerent substituted
timolol esters and checked their stability and lipophilicity. Some timolol esters in the form of their hydrochlorides
were prepared as reported earlier. 106 Using the same methodology, the hydrochloride salt of O -isobutyryl ester
was also prepared and isolated. Reaction of timolol maleate and corresponding acid chloride in acetonitrile
resulted in the formation of all other esters as fumarate salts except two. After slurry formation of timolol
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Scheme 42. Cont.

Scheme 43. Cont.

Scheme 44. Synthesis of timolol esters.

maleate in acetonitrile, it was reacted with appropriate acid chloride. HPLC analysis was also carried out after
stirring for 4 h (for aliphatic esters) or 20 h (for aromatic esters) at 80 ◦ C was carried out. Residues obtained
were separated, washed, and treated with ether or mixture of ethyl acetate, ether, and a solution of fumaric
acid in the presence of 2-propanol to get fumarate salts of timolol esters.
To overcome the systemic eﬀects and to increase the bioavailability, the amphiphilic prodrugs could be
eﬀective. Following this statement, Pech et al. 108 described the synthesis of timolol prodrugs to enhance ocular
delivery and also explained hydrolysis and conformational behavior of the synthesized compounds 114–128.
A mixture of slurried timolol maleate and palmitoyl chloride was stirred for 24 h at 80 ◦ C. Introduction of
ethylamine, extraction, and purification provided the quaternary ammonium salt. Reaction of malonic acid in
2-propanol with quaternary ammonium salt produced the desired palmitoyl timolol malonate (Scheme 45).
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Scheme 45. Synthesis of palmitoyl timolol malonate.

A novel synthetic approach to synthesize nonracemic ( S)-timolol incorporating cyclic sulfites was presented by Bredikhina et al. 109 Synthesis of scalemic β -AB (( S)-timolol) from ( S) -glycidol, utilizing cyclic
sulfites as an important intermediate, was carried out. Treatment of a mixture of (2RS, 4S )-129 with 3hydroxy-4-morpholino-1,2,3-thiadiazole (130) in the presence of DMF resulted in a mixture of isomers (2RS,
4 R)-131 (59:41, 80% yield). A double nucleophilic substituted undesirable product, 1,3-bis[(4-morpholino1,2,5-thiadiazol-3-yl)oxy]propan-2-ol, was isolated along with isomeric major products (2RS, 4R)-131 under
the applied conditions. Separation of products 131 and 1,3-bis[(4-morpholino-1,2,5-thiadiazol-3-yl)oxylpropan2-ol was carried out by column chromatography. Partial crystallization of a mixture of sulfites (131) took
place upon storage and resulted in crystals enriched in (2S , 4 R) -131. Reaction of sulfites (4 R) -131 with
t -BuNH 2 in DMF at 60–80 ◦ C furnished ( S)-4 (∼ 80% yield). The salient feature of this synthesis is the
use of chloromethyl sulfites instead of epichlorohydrin as administrated in the previous approaches. Synthesis
involving epichlorohydrin always produced a racemic mixture, while use of chloromethyl sulfites provided only
one enantiomer (Scheme 46).

Scheme 46. Synthesis of timolol from compound 129.

A bioenzymatic approach was incorporated by Tosi et al. 110 for an excellent asymmetric synthesis of
both the enantiomers of timolol. The synthetic route was started from the synthesis of 4-morpholin-4-yl-1,2,5thiadiazol-3-ol (130). Two-step treatment of 3,4-dichloro-1,2,5-thiadiazole (132) resulted in the formation of
130 (91% yield). Haloketone 133 (80% yield) was obtained by the treatment of 130 with dichloroacetone in
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dry DMF along with NaHCO 3 . The biocatalyst baker’s yeast 111 was used for the asymmetric reduction of
haloketone 133. This step was carried out using diﬀerent yeast/substrate ratios and some additives such as
glucose, allyl bromide, and allyl alcohol. The function of additives herein is to act as selective inhibitors for
the diﬀerent oxido-reductase of the multienzymatic system. 112 Levorotatory enantiomer of (2S) -1-chloro-3-[(4morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxyl]propan-2-ol (134) was the main product of the asymmetric reduction
independent of the additives; however, variable ee (59% to 87%) was achieved. Configuration of (-)-134, i.e.
(S), was determined by treating it with t -BuOK in THF at 0

◦

C to achieve the epoxide ( R)-(-)-135 113

(97% yield). Treatment of (R)-(–)-135 with t−BuNH 2 aﬀorded the R -(–)-4, timolol. To achieve (S)-(–
)-4, Mitsunobu methodology was adopted for inversion of configuration 114 and benzoate ester (R)-(–)-136
(80% yield) of (–)-134 was obtained by manipulating it with diethyl-azodicarboxylate (DEAD) and triphenyl
phosphine (PPh 3 ) . Removal of the acyl group and intramolecular alkylation of (R)-(–)-136 using t-BuOK
in THF provided the (S)-(+)-135. Reaction of intermediate ( S) -(+)-135 with t− butylamine provided the
concerned ( S)-timolol (66% yield, 87% ee) (Scheme 47).

Scheme 47. Synthesis of timolol from compound 132.

Asymmetric synthesis of (S)-timolol was presented by Jinhui et al. 115 D-mannitol was used as chiral synthon. Oxazolidine derivative was aﬀorded by treating (S)-(–)-3- t-butyl-amino-1,2-propanediol with benzaldehyde. Reaction of oxazolidine derivative with 3-chloro-4-morpholino-1,2,5-thiadiazole and t -BuOK/ t-BuOH
followed by hydrolyzation resulted in (S)-timolol.
In 2007, Narina and Sodalai 116 presented an asymmetric synthesis of (S) -timolol from readily available
reagents. The dihydroxylation of allylamine 117 and the kinetic resolution of terminal epoxides 118 are the
key features of this synthesis. The Boc- protected tert-butyl amine was alkylated with allyl bromide using
NaH to aﬀord N -tert-butyl allylamine (137). The Os-catalyzed asymmetric dihydroxylation of 137 with
(DHQ) 2 -PHAL ligand aﬀorded a chiral diol (93% yield) (138). Addition of K 2 CO 3 and MeOH in diol
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Scheme 48. Asymmetric synthesis of ( S) -timolol from compound 137.

Scheme 49. Synthesis of timolol from compound 130.
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132 and refluxing provided 2-oxazolidinone (139) 119 (95% yield, 56% ee).
chloro-4-(N -morpholino)-1,2,5-thiadiazole (98)
hydrolysis of A with 1 N NaOH in MeOH

120

31

O -alkylation of 139 using 3-

resulted in oxazolidinone A. Timolol 4 was obtained after

and then maleate salt of 4 31 (85% yield, 56% ee) was isolated

(Scheme 48). To increase the ee of timolol, a new method was adopted. O -alkylation of 3-hydroxy-4-(N morpholino)-1,2,5-thiadiazole (130) using epichlorohydrin resulted in excessive yield of racemic epoxide 135.
The hydrolytic kinetic resolution (HKR) 121,122 of 135 provided the chiral epoxide 135 (46% yield, 90% ee)
and its diol 140 (45% yield). Column chromatography was performed to separate the compounds 135 and
140. tert-Butylamine was used for ring opening of chiral epoxide 135 regiospecifically 31 and ( S) timolol 4 was
obtained. At the end, maleate salt of 4 (85% yield, 90% ee) was achieved (Scheme 49). HKR resulted in greater
optical purity of (S)-timolol but half epoxide 135 was lost. Enantioselective ring opening of terminal epoxide
using phenolic substrate followed by kinetic resolution approach was utilized. Alternatively chiral epoxide
135 could be obtained via (2 R) -1-chloro-3-[(4-morpholino-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol (134) (86%
yield, 98% ee) when (±) epichlorohydrin was treated with 3-hydroxy-4-(N -morpholino)-1,2,5-thiadizole (130)
using ( R, R)-(salen)Co(OC(CF 3 )3 ] complex and tert-butylmethyl ether at 25

◦

C. The requisite epoxide 135

◦

(97% yield) was prepared from chlorohydrin 134 using t− BuOK and THF at 0 C. Regiospecific ring opening
of chiral epoxide 135 was carried out to achieve ( S)-timolol 4, which was isolated in the form of maleate salt
(85% yield, 98% ee) (Scheme 48).
Kamal et al. 123 innovated a new synthetic route for the preparation of (R) and (S) -timolol via enzymecatalyzed resolution. 3,4-Dichloro-1,2,5-thiadiazole (132) was converted to 134 as previously reported. 110
Racemic alcohol 134 was treated with lipase and vinyl acetate in successive steps to obtain compound (R)-134
and (S)-141, separated by column chromatography. (R)-134 and (S)-141 (after deprotection) were converted
to ( S)-4 and ( R)-4 respectively, 110 which were purified by column chromatography (Scheme 50).

Scheme 50. Synthesis of timolol from compound 134.

3. Conclusion
The synthetic/medicinal value of beta-blockers is well-known. The synthetic approaches attempted so far
towards the synthesis of beta-blockers (betaxolol, metoprolol, sotalol, and timolol) have been summarized in
this article. It is evident that the synthesis of beta-blockers can be achieved by diﬀerent pathways. This article
is especially useful for scientists/chemists interested in the synthesis of analogues of beta-blockers.
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